Bernard Zovighian Biography and Net Worth

Bernard J. Zovighian has been corporate vice president since January 2016 and is currently responsible for the company’s Transcatheter Mitral and Tricuspid Therapies (TMTT) business. The patients impacted by mitral and tricuspid heart valve diseases suffer from debilitating conditions that, at best, severely diminish their quality of life, and at worst, are life threatening. As the leader for Edwards TMTT since 2018, Zovighian has established an organization focused on developing and delivering a portfolio of therapies designed to change the standard of care for mitral and tricuspid patients. Zovighian joined Edwards Lifesciences in January 2015 as vice president and general manager of the Surgical Structural Heart business, later serving as corporate vice president from 2016-2017. During his leadership of Edwards’ surgical therapies, the company received regulatory approval and launched two important breakthrough therapies globally, as well as completed an acquisition of a pioneering beating-heart repair for degenerative mitral regurgitation. Prior to joining Edwards, Zovighian held a variety of roles with increasing levels of responsibility at Johnson & Johnson (J&J) for nearly 20 years, including worldwide president of Advanced Sterilization Products, president of JJMP – J&J’s medical technology businesses in Canada – and Cordis. Zovighian has extensive senior leadership experience in the medical technology industry in Europe and North America where he has led the development and adoption of disruptive technology that has elevated the standard of care. He received a master’s degree in biomedical engineering from University of Marseille and an executive MBA from Euromed Management, both in France.